1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Senate Wants To Keep FDA Device Center At Near-Current Levels In 2020 In 'Minibus' Funding Bill

 
• By Sue Darcey

The US Senate Appropriations Committee has drafted a “minibus” bill covering funding in fiscal year 2020 for five agencies – including the FDA – that would give the agency's device center only $387m. That would keep the center’s spending level approximately the same as it was in FY 2019. The Senate’s proposed spending level is in sharp contrast to what the US House wants for the device center, which is $420m.

WASHINGTON - JULY 18: A sign at the entrance to a Senate Appropriations Committee hearing room in Washington, DC on July 18, 2017. The US Senate is the upper chamber of the United States Congress. - Image

The Senate Appropriations Committee wants to keep the congressional spending portion of the US Food and Drug Administration’s Center for Devices and Radiological Health at approximately $387m in fiscal year 2020 – the same as FY 2019. Such a move would prevent CDRH from carrying out many new programs it had planned.

The revised budget deals for each agency are spelled out in H.R. 3055, a five-agency “minibus” spending bill for FY 2020 that Senate intends to pass by 21 November. Since the Senate and House did not reach agreement on overall government spending levels before 1 October when the new fiscal year began, federal agencies have been limping along on a continuing resolution bill Congress approved late last month that keeps spending at FY 2019 levels – at least until the 21 November deadline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By Elizabeth Orr

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By Elizabeth Orr

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 
• By Brian Bossetta

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

More from Policy & Regulation

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By Elizabeth Orr

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By Elizabeth Orr

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 
• By Brian Bossetta

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.